Stock Information
symbol line chart

ADIAAdia Med Inc.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

N/A

Location

Florida, USA

Exchange

OTC

Summary

Adia Nutrition, Inc.

Company Info

CEO

N/A

Location

Florida, USA

Exchange

OTC

Summary

Adia Nutrition, Inc.

AI Insights for ADIA
5 min read

Quick Summary

Adia Med Inc., historically associated with Adia Nutrition, is an OTC-listed microcap company that has described operations in probiotic nutrition and newer regenerative medicine services. The company’s legacy business involved probiotic drink mixes and probiotic chews sold online and through nutrition-oriented retail channels. Its more recent public-facing activity appears focused on Adia Med clinics, regenerative therapies, diagnostics, stem cell or exosome-related offerings, and clinical programs. Its main customers appear to include wellness consumers, nutrition-product buyers, clinic patients, medical practitioners, and partner clinics interested in integrating regenerative therapies. The company is very small by public-market standards, with reported quarterly revenue of about $485,385 and net income of about $40,418, so its business profile may change quickly as new services are introduced.

Strengths

•

Adia’s primary strength is that it has a recognizable wellness-oriented history and a product background in probiotics, which gives it some connection to the broader consumer health market.

•

The company has reported positive net income for the referenced quarter, which is notable for a small OTC healthcare company.

•

Its newer regenerative medicine strategy could attract attention because stem cell, exosome, diagnostics, and clinic-based therapies are areas of high investor interest.

•

The appointment of medical and revenue leadership may improve credibility if those hires translate into disciplined operations and transparent execution.

•

The company’s small size may also allow it to pivot quickly, launch targeted programs, and benefit disproportionately from any successful clinical or commercial milestone.

Key Risks

•

The company faces substantial clinical, regulatory, financial, and reputational risks.

•

Stem cell and exosome-related treatments are heavily scrutinized, and any failure to meet regulatory or ethical standards could damage the company’s prospects.

•

The autism trial is long in duration and may not produce favorable results, may face recruitment challenges, or may be criticized if study design, cost, or claims are viewed skeptically.

•

OTC liquidity risk is significant, because thin trading can amplify both gains and losses and may make it difficult for investors to enter or exit positions efficiently.

What to Watch

During the most recent period, the company’s key reported financial data showed total revenue of about $485,385, gross profit of about $282,580, operating income of about $51,829, and net income of about $40,418.
Recent company-related news indicated that Adia Nutrition appointed Dawn Bell as Chief Revenue Officer of ADIA Labs to support revenue growth and clinic-partner development.
The company also announced recruitment activity for a 24-month clinical trial in Winter Park, Florida, studying AdiaVita with glutathione for children with autism symptoms.
Another notable development was the appointment of radiation oncologist Evan Thomas, MD, PhD, as Independent Medical Director for Adia Med.
These events suggest management is trying to reposition or expand the business from legacy probiotic nutrition into clinical, diagnostic, and regenerative health services.

Price Drivers

•

ADIA’s stock price is likely driven by a combination of microcap liquidity, clinical news, revenue growth, and investor reaction to regenerative medicine developments.

•

The company trades on the OTC market, and recent volume appears modest, so relatively small buy or sell orders can have an outsized impact on price.

•

Reported revenue of about $485,385 and net income of about $40,418 suggest the company is operating at a small scale, making each new clinic initiative or partnership potentially important to investor perception.

•

The stock’s 52-week range of $0.03 to $0.28 indicates high volatility and sensitivity to sentiment.

•

Price movement may also be affected by confusion with unrelated ADIA references, because several recent news items using the ADIA name refer to the Abu Dhabi Investment Authority rather than Adia Med Inc.

Recent News

•

Recent company-specific news includes Adia Nutrition’s appointment of Dawn Bell as Chief Revenue Officer of ADIA Labs, with a focus on revenue growth and support for clinic partners.

•

The company also announced that Adia Med began recruiting for a 24-month autism-related clinical trial in Winter Park, Florida, involving AdiaVita and glutathione.

•

Another company-specific development was the appointment of Evan Thomas, MD, PhD, as Independent Medical Director to oversee clinical operations and protocols.

•

Many other recent headlines containing the term ADIA are not about Adia Med Inc. and instead refer to the Abu Dhabi Investment Authority and its investments in areas such as private credit, insurance distribution, infrastructure, and funds.

•

Investors should separate those unrelated sovereign-wealth headlines from news that actually affects the OTC-listed ADIA company.

Market Trends

•

Several broader market trends affect Adia’s outlook, including rising consumer interest in wellness, probiotics, regenerative medicine, and personalized health services.

•

The supplement market remains large but competitive, with established brands dominating distribution and customer trust.

•

Regenerative medicine and exosome-related therapies are attracting attention, but they also face increasing regulatory scrutiny and demand for credible clinical evidence.

•

Autism-related treatments are a sensitive and highly scrutinized area, so companies operating in this space must be careful with claims, trial design, patient safety, and communication.

•

In the public markets, microcap healthcare stocks remain highly sentiment-driven, and OTC companies can experience sharp moves based on news, liquidity, promotional activity, or changes in risk appetite.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on ADIA

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show